Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2441156rdf:typepubmed:Citationlld:pubmed
pubmed-article:2441156lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2441156lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:2441156lifeskim:mentionsumls-concept:C0443315lld:lifeskim
pubmed-article:2441156lifeskim:mentionsumls-concept:C1533685lld:lifeskim
pubmed-article:2441156lifeskim:mentionsumls-concept:C0027481lld:lifeskim
pubmed-article:2441156lifeskim:mentionsumls-concept:C0205307lld:lifeskim
pubmed-article:2441156lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:2441156lifeskim:mentionsumls-concept:C0102586lld:lifeskim
pubmed-article:2441156pubmed:issue1lld:pubmed
pubmed-article:2441156pubmed:dateCreated1987-9-18lld:pubmed
pubmed-article:2441156pubmed:abstractTextThe plasma hormone and urine effects of 100 micrograms of alpha-human atrial natriuretic peptide (alpha-hANP) given by subcutaneous (s.c.) injection, were studied in eight healthy male volunteers. A control s.c. injection was administered on a separate day, and the study was single-blind. The peak immunoreactive atrial natriuretic peptide (IR-ANP) level of 29.4 +/- 4.4 pmol/L reached at 5 min was threefold higher than on the control day. Area under the IR-ANP response curve was approximately 1/32 of that after the same dose of alpha-hANP given by intravenous (i.v.) injection. alpha-hANP s.c. injection was not associated with significant effects on plasma renin activity (PRA), plasma aldosterone, or urine electrolyte excretion. It was concluded that only a small percentage of intact alpha-hANP is absorbed into the circulation after s.c. injection. With the dose of peptide and the injection vehicle chosen, alpha-hANP had little or no biological effect.lld:pubmed
pubmed-article:2441156pubmed:languageenglld:pubmed
pubmed-article:2441156pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2441156pubmed:citationSubsetIMlld:pubmed
pubmed-article:2441156pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2441156pubmed:statusMEDLINElld:pubmed
pubmed-article:2441156pubmed:monthJullld:pubmed
pubmed-article:2441156pubmed:issn0160-2446lld:pubmed
pubmed-article:2441156pubmed:authorpubmed-author:EspinerE AEAlld:pubmed
pubmed-article:2441156pubmed:authorpubmed-author:NichollsM GMGlld:pubmed
pubmed-article:2441156pubmed:authorpubmed-author:IkramHHlld:pubmed
pubmed-article:2441156pubmed:authorpubmed-author:YandleT GTGlld:pubmed
pubmed-article:2441156pubmed:authorpubmed-author:CrozierI GIGlld:pubmed
pubmed-article:2441156pubmed:issnTypePrintlld:pubmed
pubmed-article:2441156pubmed:volume10lld:pubmed
pubmed-article:2441156pubmed:ownerNLMlld:pubmed
pubmed-article:2441156pubmed:authorsCompleteYlld:pubmed
pubmed-article:2441156pubmed:pagination72-5lld:pubmed
pubmed-article:2441156pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2441156pubmed:meshHeadingpubmed-meshheading:2441156-...lld:pubmed
pubmed-article:2441156pubmed:meshHeadingpubmed-meshheading:2441156-...lld:pubmed
pubmed-article:2441156pubmed:meshHeadingpubmed-meshheading:2441156-...lld:pubmed
pubmed-article:2441156pubmed:meshHeadingpubmed-meshheading:2441156-...lld:pubmed
pubmed-article:2441156pubmed:meshHeadingpubmed-meshheading:2441156-...lld:pubmed
pubmed-article:2441156pubmed:meshHeadingpubmed-meshheading:2441156-...lld:pubmed
pubmed-article:2441156pubmed:meshHeadingpubmed-meshheading:2441156-...lld:pubmed
pubmed-article:2441156pubmed:year1987lld:pubmed
pubmed-article:2441156pubmed:articleTitlePlasma immunoreactive atrial natriuretic peptide levels after subcutaneous alpha-hANP injection in normal humans.lld:pubmed
pubmed-article:2441156pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2441156pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2441156pubmed:publicationTypeControlled Clinical Triallld:pubmed
pubmed-article:2441156pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed